Nektar Therapeutics
NKTR
$57.13
$2.284.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.50% | 6.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.50% | 6.84% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 5.50% | 6.84% | |||
| SG&A Expenses | -5.87% | -29.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.74% | -14.35% | |||
| Operating Income | 11.88% | 19.35% | |||
| Income Before Tax | 14.90% | 17.80% | |||
| Income Tax Expenses | 82.45% | -461.54% | |||
| Earnings from Continuing Operations | 14.60% | 18.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.60% | 18.26% | |||
| EBIT | 11.88% | 19.35% | |||
| EBITDA | 11.90% | 19.05% | |||
| EPS Basic | 36.50% | 18.41% | |||
| Normalized Basic EPS | 36.29% | 18.56% | |||
| EPS Diluted | 36.50% | 18.41% | |||
| Normalized Diluted EPS | 36.29% | 18.56% | |||
| Average Basic Shares Outstanding | 34.49% | 0.18% | |||
| Average Diluted Shares Outstanding | 34.49% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||